$3.24
0.072.21%
Last update: 3:38 PM
15 minutes delayed
Comments
Loading...
OncoCyte
OCXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
OncoCyte (NASDAQ:OCX) Stock, Analyst Ratings, Price Targets, Forecasts
OncoCyte Corp has a consensus price target of $3.35 based on the ratings of 6 analysts. The high is $5 issued by Benchmark on April 15, 2024. The low is $0.5 issued by Lake Street on December 1, 2022. The 3 most-recent analyst ratings were released by Needham, Needham, and Stephens & Co. on May 16, 2024, April 24, 2024, and April 17, 2024, respectively. With an average price target of $4.17 between Needham, Needham, and Stephens & Co., there's an implied 25.13% upside for OncoCyte Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Stephens & Co.
Benchmark
Piper Sandler
Lake Street
1calculated from analyst ratings
Analyst Ratings for OncoCyte
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2024 | Buy Now | 27.63% | Needham | Mike Matson | → $4.25 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2024 | Buy Now | 27.63% | Needham | Mike Matson | $3.6 → $4.25 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 20.12% | Stephens & Co. | Mason Carrico | → $4 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 04/15/2024 | Buy Now | 50.15% | Benchmark | Bruce Jackson | → $5 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 11/13/2023 | Buy Now | -9.91% | Piper Sandler | David Westenberg | $3.5 → $3 | Maintains | Neutral | Get Alert |
| 11/09/2023 | Buy Now | 8.11% | Needham | Mike Matson | $4.25 → $3.6 | Maintains | Buy | Get Alert |
| 08/24/2023 | Buy Now | 50.15% | Benchmark | Bruce Jackson | $9 → $5 | Maintains | Speculative Buy | Get Alert |
| 08/15/2023 | Buy Now | 5.11% | Piper Sandler | David Westenberg | $6 → $3.5 | Maintains | Neutral | Get Alert |
| 08/10/2023 | Buy Now | 27.63% | Needham | Mike Matson | $9 → $4.25 | Maintains | Buy | Get Alert |
| 04/04/2023 | Buy Now | -86.49% | Needham | Mike Matson | $28 → $9 | Maintains | Buy | Get Alert |
| 12/01/2022 | Buy Now | -84.98% | Lake Street | Thomas Flaten | $60 → $10 | Downgrade | Buy → Hold | Get Alert |
| 11/18/2022 | Buy Now | -84.98% | Piper Sandler | David Westenberg | $20 → $10 | Downgrade | Overweight → Neutral | Get Alert |
| 11/14/2022 | Buy Now | -69.97% | Piper Sandler | David Westenberg | $30 → $20 | Maintains | Overweight | Get Alert |
| 11/11/2022 | Buy Now | -57.96% | Needham | Mike Matson | $42 → $28 | Maintains | Buy | Get Alert |
| 08/17/2022 | Buy Now | -54.95% | Piper Sandler | David Westenberg | $28 → $30 | Maintains | Overweight | Get Alert |
| 08/11/2022 | Buy Now | -9.91% | Lake Street | Thomas Flaten | $120 → $60 | Maintains | Buy | Get Alert |
| 08/11/2022 | Buy Now | -36.94% | Needham | Mike Matson | $45 → $42 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | — | Stephens & Co. | Mason Carrico | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 05/16/2022 | Buy Now | -57.96% | Piper Sandler | David Westenberg | $36 → $28 | Maintains | Overweight | Get Alert |
| 05/12/2022 | Buy Now | -32.43% | Needham | Mike Matson | $80 → $45 | Maintains | Buy | Get Alert |
| 03/18/2022 | Buy Now | -45.95% | Piper Sandler | David Westenberg | $62 → $36 | Maintains | Overweight | Get Alert |
| 03/14/2022 | Buy Now | — | Keybanc | Paul Knight | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 03/11/2022 | Buy Now | 80.18% | Lake Street | Thomas Flaten | $220 → $120 | Maintains | Buy | Get Alert |
| 03/11/2022 | Buy Now | 20.12% | Needham | Mike Matson | $100 → $80 | Maintains | Buy | Get Alert |
| 01/07/2022 | Buy Now | -6.91% | Stephens & Co. | Mason Carrico | → $62 | Initiates | → Overweight | Get Alert |
| 12/16/2021 | Buy Now | 50.15% | Needham | Mike Matson | — | Maintains | Buy | Get Alert |
| 11/10/2021 | Buy Now | 110.21% | Needham | Mike Matson | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for OncoCyte (OCX) stock?
The latest price target for OncoCyte (NASDAQ:OCX) was reported by Needham on May 16, 2024. The analyst firm set a price target for $4.25 expecting OCX to rise to within 12 months (a possible 31.17% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for OncoCyte (OCX)?
The latest analyst rating for OncoCyte (NASDAQ:OCX) was provided by Needham, and OncoCyte reiterated their buy rating.
When was the last upgrade for OncoCyte (OCX)?
There is no last upgrade for OncoCyte
When was the last downgrade for OncoCyte (OCX)?
The last downgrade for OncoCyte Corp happened on December 1, 2022 when Lake Street changed their price target from $3 to $0.5 for OncoCyte Corp.
When is the next analyst rating going to be posted or updated for OncoCyte (OCX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OncoCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OncoCyte was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
Is the Analyst Rating OncoCyte (OCX) correct?
While ratings are subjective and will change, the latest OncoCyte (OCX) rating was a reiterated with a price target of $4.25 to $4.25. The current price OncoCyte (OCX) is trading at is $3.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.